Atrial fibrillation is the most common sustained cardiac arrhythmia in clinical practice and conveys a 4- to 5-fold increased risk of stroke; yet, it often goes undiagnosed and untreated in a primary care setting. In the program, Dr. Ty Gluckman discusses how to recognize patients at high risk for AF, evaluate patients newly diagnosed with AF, assess risk of bleeding and thromboembolism, and apply evidence-based recommendations to reduce thromboembolic risk. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on 8/4/2020, and they are subject to change as new information is published.
Episode 2: Bridging the Gap: Conversations with Dr. Hall
This session will provide an overview of the best practices in the treatment of cardiovascular problems in African Americans with a focus on hypertension, heart failure, stroke, vascular disease, arrhythmias, and thrombosis. Overarching trends in salt sensitivity, smoking, and medication adherence will also be reviewed, as well as opportunities to positively impact behavior. Dr. Hall is a Primary Care Physician and an expert in Black American Health and Healthcare. He is the former chair of the Ohio Commission on Minority Health, Director of the National Center for African American Health, Research, Education and Policy at Cleveland State University, and Author of “Patient-Centered Clinical Care for African Americans: A Concise, Evidence-Based Guide to Important Differences and Better Outcomes”. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 08/11/2020 and they are subject to change as new information is published.
Watch distinguished faculty from Northwestern University examine clinical trial data and the latest evidence-based guidelines for hypercholesterolemia to help you develop a practical approach to lipid management for primary care. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on August 12, 2020, and they are subject to change as new information is published.
Heart failure (HF) affects 6.2 million people in the United States, with 1 million new cases occurring annually and a resultant 1 million hospitalizations, which translates into an annual estimated cost of over $30 billion dollars. Mortality with this condition is high, approximately 50% at five years. Implementation of the advances in management of heart failure have the potential to improve patients' quality of life, reduce the need for hospitalizations, reduce total medical costs, and prolong survival. This lecture will review the current evidence-based, guideline-recommended diagnosis and management of heart failure. You will learn the essential roles of evidence-based heart failure medications, device therapy, patient education, and disease management.
Join cardiologist Ty Gluckman, MD in part one of this two part podcast series as he reviews the latest guideline-based management of heart failure with reduced ejection fraction (HFrEF), bringing to light major advances in the past years and evidence supporting these advances. Listen to part two of this podcast series here: https://www.pri-med.com/online-education/podcast/gluckman-hf-2
Join cardiologist Ty Gluckman, MD in part two of this two-part podcast series as he reviews the unmet needs of patients with heart failure with reduced ejection fraction (HFrEF) and discusses the evidence on emerging pharmacologic treatments for HFrEF. He will describe the current data in HFrEF for the following drug classes: SGLT2 inhibitors, soluble guanylate cyclase stimulators, and selective cardiac myosin activators.
Effective Tool or Diet Fad? Can Intermittent Fasting Decrease Weight and Improve Cardiovascular Markers? - Frankly Speaking EP 165
Guest: Susan Feeney, DNP, FNP-BCMusic Credit: Richard Onorato
Obesity, dyslipidemia, and hypertension are significant challenges to public health and impact a growing number of Americans. Weight loss and dietary changes are effective in preventing CVD and DMII and reducing cardiometabolic complications, but can be difficult for many people. Growing evidence supports the use of timed fasting to promote weight loss and reduce these complications. Join us as we discuss a recent study that shows promising data regarding a 10-hour feeding window and improved CV markers.
Guest: Jill Terrien PhD, ANP-BCMusic Credit: Richard Onorato
In this episodes, we will discuss a systematic review and meta-analysis that examines outcomes from the use of furosemide compared to torsemide in patients with congestive heart failure.
Guest: Robert A. Baldor, MD, FAAFPMusic Credit: Richard Onorato
Join us as we review a landmark paper that reached the conclusion that limiting red meat would not have a large impact on patient outcomes.
This initiative aims to increase understanding among cardiologists about adjunctive LDL-C-lowering therapies and their potential role in reducing residual ASCVD risk. During this series, national lipid expert faculty will discuss the incidence of and diagnostic criteria for statin intolerance, explain the mechanistic rationale for lowering LDL-C through nonstatin therapies, and explore novel targets and treatment pathways. It is expected to improve cardiologists’ management of patients with ‘tough-to-treat’ cholesterol according to the 2018 American Heart Association (AHA)/American College of Cardiology (ACC)/Multi-society Cholesterol Guidelines. Learners will have the opportunity to gain practical clinical perspectives during expert case study discussions. The patient scenarios will discuss how new treatment options may fit into the current therapeutic landscape.
Guest: Susan Feeney, DNP, FNP-BC, NP-CMusic Credit: Richard Onorato
During this episode, we will review some of the recent data on Vitamin D supplementation and its association with cardiovascular outcomes, falls, vertigo, and general health.
Guest: Alan Ehrlich MD Music Credit: Richard Onorato
For patients with established cardiovascular disease,aspirin is clearly beneficial as part of secondary prevention. However, when used as primary prevention in patients without documented cardiovascular disease, its benefit is much less certain. This podcast will explore 3 recent trials that evaluated aspirin in different populations and found nobenefit for its use as primary prevention.